Bio-Rad Laboratories, Inc. (BIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151207,
    "name": "Bio-Rad Laboratories, Inc.",
    "stock_name": "Bio-Rad Laboratories, Inc.",
    "full_name": "Bio-Rad Laboratories, Inc.",
    "name_url": "stocks-analysis/bio-rad-laboratories-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "320.06",
    "chg": -0.28,
    "chgp": "-0.09%",
    "dir": -1,
    "prev_price": "320.34",
    "mcapval": "7,936.73",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US0905722072",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "52.21 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bio-rad-laboratories-inc-1151207-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bio-Rad Laboratories Adjusts Valuation Amidst Financial Performance Challenges and Market Reassessment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bio-rad-laboratories-downgraded-from-hold-to-sell-amid-valuation-shift-3640175",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioRadLaborator_mojoScore_3640175.png",
        "date": "2025-10-23 15:38:12",
        "description": "Bio-Rad Laboratories, Inc. has experienced a change in its valuation grade, now categorized as fair. This adjustment is based on a reassessment of financial metrics, including a P/E ratio of 16.20 and a price-to-book value of 0.91, alongside challenges in sales growth and recent profit declines."
      },
      {
        "title": "Is Bio-Rad Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-rad-laboratories-inc-overvalued-or-undervalued-3637246",
        "imagepath": "",
        "date": "2025-10-21 11:58:31",
        "description": "As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E ratio of 21.83, while QIAGEN NV stands at 24.20, suggesting that Bio-Rad is trading at a significant discount relative to these competitors.\n\nDespite the recent fair valuation, Bio-Rad's stock performance has lagged behind the S&P 500, with a year-to-date return of -5.63% compared to the index's 13.30%. Over the past five years, the company's return has been -44.30%, while the S&P 500 has gained 91.29%. This underperformance reinforces the notion that Bio-Rad is fairly valued, as it struggles to keep pace with broader market trends...."
      },
      {
        "title": "Bio-Rad Laboratories Experiences Valuation Adjustment Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-rad-laboratories-valuation-grade-downgraded-from-attractive-to-fair-amid-stock-price-decline-3640533",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioRadLaborator_valuationdot_3640533.png",
        "date": "2025-10-20 15:36:47",
        "description": "Bio-Rad Laboratories, Inc. has recently adjusted its valuation, reporting a P/E ratio of 5 and a low PEG ratio of 0.07. Its performance indicators reveal a year-to-date return of -5.63%, contrasting with the S&P 500's gain, underscoring the challenges in a competitive Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Bio-Rad Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-rad-laboratories-inc-overvalued-or-undervalued-3631656",
        "imagepath": "",
        "date": "2025-10-19 11:54:17",
        "description": "As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 10.62, indicating a reasonable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the PEG ratio is notably low at 0.07, suggesting potential undervaluation based on growth expectations.\n\nIn comparison to its peers, Bio-Rad's P/E ratio of 16.20 is lower than Hologic, Inc. at 21.83 and QIAGEN NV at 24.20, both of which are also considered fairly valued. However, it is worth noting that The Cooper Companies, Inc. is categorized as expensive with a P/E of 34.28. Despite a recent strong performance with a 1-week return of 4.13% compared to the S&P 500's 1.70%, Bio-Rad has underperfo..."
      },
      {
        "title": "Bio-Rad Laboratories, Inc. Announces Revision in Stock Evaluation Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-rad-laboratories-inc-technical-trend-shifts-from-mildly-bearish-to-mildly-bullish-3579738",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/BioRadLaborator_technicaldot_3579738.png",
        "date": "2025-09-29 15:51:36",
        "description": "Bio-Rad Laboratories, Inc. has recently seen a revision in its evaluation, with its stock price at $271.36. The company has faced notable volatility over the past year, with a high of $387.99 and a low of $211.43, while its performance has lagged behind the S&P 500."
      },
      {
        "title": "Bio-Rad Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bio-rad-laboratories-forms-golden-cross-signaling-potential-bullish-breakout-3565410",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/BioRadLaborator_goldencross_3565410.png",
        "date": "2025-09-24 14:18:47",
        "description": "Bio-Rad Laboratories, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with bullish signals on daily and weekly moving averages. However, the stock has underperformed over the past year, raising caution among investors regarding its future performance."
      },
      {
        "title": "Is Bio-Rad Laboratories, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-rad-laboratories-inc-technically-bullish-or-bearish-3545079",
        "imagepath": "",
        "date": "2025-09-20 19:03:06",
        "description": "As of 25 August 2025, the technical trend for Bio-Rad Laboratories, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum in the short term. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish across both timeframes. Overall, the indicators suggest a mildly bearish stance.\n\nIn terms of performance, Bio-Rad has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%, and a one-year return of -15.85% versus 17.14% for the benchmark...."
      },
      {
        "title": "Is Bio-Rad Laboratories, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bio-rad-laboratories-inc-overvalued-or-undervalued-3541804",
        "imagepath": "",
        "date": "2025-09-20 17:36:40",
        "description": "As of 22 August 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E of 21.83, while QIAGEN NV stands at a P/E of 24.20, indicating that Bio-Rad is trading at a significant discount relative to these competitors.\n\nDespite its fair valuation, Bio-Rad has underperformed against the S&P 500, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%. Over the past three years, the company has seen a decline of -36.13%, while the S&P 500 has gained 70.41%, further emphasizing the challenges Bio-Rad faces in the market...."
      }
    ],
    "total": 13,
    "sid": "1151207",
    "stock_news_url": "https://www.marketsmojo.com/news/bio-rad-laboratories-inc-1151207"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Bio-Rad Laboratories Adjusts Valuation Amidst Financial Performance Challenges and Market Reassessment

2025-10-23 15:38:12

Bio-Rad Laboratories, Inc. has experienced a change in its valuation grade, now categorized as fair. This adjustment is based on a reassessment of financial metrics, including a P/E ratio of 16.20 and a price-to-book value of 0.91, alongside challenges in sales growth and recent profit declines.

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

2025-10-21 11:58:31

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E ratio of 21.83, while QIAGEN NV stands at 24.20, suggesting that Bio-Rad is trading at a significant discount relative to these competitors. Despite the recent fair valuation, Bio-Rad's stock performance has lagged behind the S&P 500, with a year-to-date return of -5.63% compared to the index's 13.30%. Over the past five years, the company's return has been -44.30%, while the S&P 500 has gained 91.29%. This underperformance reinforces the notion that Bio-Rad is fairly valued, as it struggles to keep pace with broader market trends....

Bio-Rad Laboratories Experiences Valuation Adjustment Amid Competitive Market Landscape

2025-10-20 15:36:47

Bio-Rad Laboratories, Inc. has recently adjusted its valuation, reporting a P/E ratio of 5 and a low PEG ratio of 0.07. Its performance indicators reveal a year-to-date return of -5.63%, contrasting with the S&P 500's gain, underscoring the challenges in a competitive Pharmaceuticals & Biotechnology sector.

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

2025-10-19 11:54:17

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 10.62, indicating a reasonable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the PEG ratio is notably low at 0.07, suggesting potential undervaluation based on growth expectations. In comparison to its peers, Bio-Rad's P/E ratio of 16.20 is lower than Hologic, Inc. at 21.83 and QIAGEN NV at 24.20, both of which are also considered fairly valued. However, it is worth noting that The Cooper Companies, Inc. is categorized as expensive with a P/E of 34.28. Despite a recent strong performance with a 1-week return of 4.13% compared to the S&P 500's 1.70%, Bio-Rad has underperfo...

Bio-Rad Laboratories, Inc. Announces Revision in Stock Evaluation Amid Market Volatility

2025-09-29 15:51:36

Bio-Rad Laboratories, Inc. has recently seen a revision in its evaluation, with its stock price at $271.36. The company has faced notable volatility over the past year, with a high of $387.99 and a low of $211.43, while its performance has lagged behind the S&P 500.

Bio-Rad Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout

2025-09-24 14:18:47

Bio-Rad Laboratories, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with bullish signals on daily and weekly moving averages. However, the stock has underperformed over the past year, raising caution among investors regarding its future performance.

Is Bio-Rad Laboratories, Inc. technically bullish or bearish?

2025-09-20 19:03:06

As of 25 August 2025, the technical trend for Bio-Rad Laboratories, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum in the short term. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish across both timeframes. Overall, the indicators suggest a mildly bearish stance. In terms of performance, Bio-Rad has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%, and a one-year return of -15.85% versus 17.14% for the benchmark....

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

2025-09-20 17:36:40

As of 22 August 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E of 21.83, while QIAGEN NV stands at a P/E of 24.20, indicating that Bio-Rad is trading at a significant discount relative to these competitors. Despite its fair valuation, Bio-Rad has underperformed against the S&P 500, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%. Over the past three years, the company has seen a decline of -36.13%, while the S&P 500 has gained 70.41%, further emphasizing the challenges Bio-Rad faces in the market....

View All News